Literature DB >> 25658560

Recurrent Clostridium difficile infection is associated with increased mortality.

M A Olsen1, Y Yan2, K A Reske3, M D Zilberberg4, E R Dubberke3.   

Abstract

Clostridium difficile infections (CDI) are associated with decreased survival, and up to 30% of CDI patients may experience a recurrence. Data on the impact of recurrent CDI on mortality are scarce. The purpose of this study was to determine whether recurrent CDI was independently associated with decreased 6-month survival compared with patients with CDI who did not develop a recurrence. We performed a retrospective cohort study at an academic, urban, tertiary care hospital. Data were collected from the electronic medical record and chart review. CDI patients were followed for 180 days from the end of their index hospital discharge or end of index CDI antibiotic treatment, whichever was later, to determine mortality. Kaplan-Meier analysis was used to compare patient mortality by recurrent CDI status. Cox proportional hazards models were used to determine independent risk factors for death within 180 days. In all, 3958 patients aged ≥ 18 years who developed an initial CDI episode from 2003 to 2009, including 421 patients with recurrent CDI, were included in the study. Thirty-six per cent of persons with recurrent CDI died within 180 days, compared with 26% of persons without CDI recurrence (log-rank p <0.001). Recurrent CDI was associated with significantly higher hazards of death within 180 days, adjusting for demographics, comorbidities and medications received during the index CDI hospitalization (hazard ratio 1.33; 95% CI 1.12-1.58). Recurrent CDI is associated with significantly increased risk of death within 6 months after completion of their initial CDI treatment compared with CDI patients who do not develop a recurrence.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; cohort; epidemiology; mortality; recurrence; survival

Mesh:

Year:  2014        PMID: 25658560     DOI: 10.1016/j.cmi.2014.08.017

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  45 in total

1.  Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality.

Authors:  Maddalena Alessandra Wu; Federica Leidi
Journal:  Intern Emerg Med       Date:  2017-07-05       Impact factor: 3.397

Review 2.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

3.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

Review 4.  Treatment of Clostridioides (Clostridium) difficile infection.

Authors:  Jarmo Oksi; Veli-Jukka Anttila; Eero Mattila
Journal:  Ann Med       Date:  2019-12-13       Impact factor: 4.709

5.  Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study.

Authors:  Jennifer L Kuntz; Jennifer M Baker; Patricia Kipnis; Sherian Xu Li; Vincent Liu; Yang Xie; Stephen Marcella; Gabriel J Escobar
Journal:  Infect Control Hosp Epidemiol       Date:  2016-10-20       Impact factor: 3.254

6.  Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.

Authors:  Marie Pichenot; Rozenn Héquette-Ruz; Remi Le Guern; Bruno Grandbastien; Clément Charlet; Frédéric Wallet; Sophie Schiettecatte; Fanny Loeuillet; Benoit Guery; Tatiana Galperine
Journal:  Infection       Date:  2017-01-24       Impact factor: 3.553

Review 7.  The gut microbiota in transplant patients.

Authors:  Pearlie P Chong; Andrew Y Koh
Journal:  Blood Rev       Date:  2019-08-29       Impact factor: 8.250

8.  Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.

Authors:  Roshan Razik; Amir Rumman; Zoya Bahreini; Allison McGeer; Geoffrey C Nguyen
Journal:  Am J Gastroenterol       Date:  2016-05-24       Impact factor: 10.864

9.  Predictors of Mortality Among a National Cohort of Veterans With Recurrent Clostridium difficile Infection.

Authors:  Haley J Appaneal; Aisling R Caffrey; Maya Beganovic; Sanja Avramovic; Kerry L LaPlante
Journal:  Open Forum Infect Dis       Date:  2018-07-19       Impact factor: 3.835

10.  THAs Performed Within 6 Months of Clostridioides difficile Infection Are Associated with Increased Risk of 90-Day Complications.

Authors:  Scott J Douglas; Ethan A Remily; Oliver C Sax; Sahir S Pervaiz; Evan B Polsky; Ronald E Delanois
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.